Hong Kong International Professional Medical Examination Association: Fupirtide Bivalent Vaccination Guide

Read Time:2 Minute, 57 Second

On January 8, 2023, the Mainland and Hong Kong and Macao will officially open customs, but due to the recent severe situation of recurring epidemics in many parts of the country and the high incidence of influenza in winter, the need to receive the fourth dose of New Crown vaccine has become a topic of concern.

In the past, mainland residents may be more familiar with Beijing Biological and Beijing Kexing’s New Crown vaccine, but they know little about Fubitai, the mRNA New Crown vaccine.

Fubitai BNT162b2 and Fubitai bivalent vaccine are officially registered as China Hong Kong drugs/products (biological products). Among them, Fupirtide BNT162b2 is registered for basic immunization for people aged 12 years and above, and Fupirtide bivalent vaccine is registered for booster vaccination for people aged 12 years and above. As an iteration and upgrade of Fupirtide BNT162b2, Fupirtide bivalent vaccine not only protects against the original strain, but also against the currently prevalent Omicron mutant strain.

What are the groups for which the “Fubitai” mRNA vaccine is indicated?

Fupirtide mRNA vaccine is especially suitable for elderly people and people with low immune function such as chronic underlying diseases. It can be used as a booster for those who have completed the first series (doses 1 and 2) of inactivated vaccines (biologic, Kexin, and Kangtai) to obtain better protection.

If the first 2 doses of inactivated vaccine (biologic, Coxin, Contagion) were given, the first booster (i.e., dose 3) is recommended for the mRNA vaccine.

If the first 3 doses of vaccine were inactivated, the 2nd booster (i.e., dose 4) is also recommended for the mRNA vaccine.
For those who have already received inactivated, mRNA or other technical routes of the new crown vaccine, it is recommended that mRNA vaccine be preferred as a booster, especially for those who have completed the initial inactivated vaccine series, a sequential vaccination with mRNA vaccine as a booster can provide better protection.

Is Fibrate bivalent vaccine necessary?

The Fibrate vaccine is available to adults and people over 16 years of age, and it protects against COVID-19 by causing the immune system to produce antibodies and blood cells against the virus. according to the results of global phase III clinical trials, Fibrate has been shown to be 95% effective in preventing new coronavirus infections in adolescents, older adults and those with underlying disease, and over 94% effective in adults over 65 years of age. The effectiveness was over 94%. So, for your health, it is still necessary to get vaccinated!

In addition, the bivalent vaccine against Omicron BA.4/BA.5 subline variants (including BA.4.6, BA.2.75.2, BQ.1.1 and XBB.1), which are currently prevalent in Hong Kong, China and many Asian countries and regions, produced a higher immune response compared to the original strain, and the safety and tolerability of the two vaccines were similar. An analysis of the antibody response to the Omicron new subline variant of the vaccine showed an 8.7-fold and 4.8-fold increase in neutralizing antibody titers against BQ.1.1 and XBB.1, respectively, after administration of the bivalent vaccine.

Vaccination against neocoronavirus is the most economical and effective means of preventing and controlling neocoronavirus infection. However, the antibody level of the vaccinated population gradually decreases over time, and the protective effect gradually decreases, while the immune memory cells of the organism can be evoked in a short period of time by booster vaccination, which can effectively raise the antibody level.